Patient characteristics
| Characteristic . | Value . |
|---|---|
| No. | 32 |
| Median age, y | 55 |
| Range | 18-81 |
| Sex, male/female | 20/12 |
| Stage | |
| IE | 19 |
| IIE | 3 |
| IV | 10 |
| B-symptom (%) | 13 (41) |
| LDH elevation (%) | 12 (38) |
| Performance status > 1 (%) | 4 (13) |
| International Prognostic Index high-intermediate/high (%) | 10 (31) |
| Origin | |
| Nasal | 29 |
| Extranasal | 3 |
| Treatment | |
| Radiotherapy | 2 |
| Concurrent chemoradiotherapy | 16 |
| Radiotherapy followed by chemotherapy | 8 |
| Chemotherapy | 6 |
| Response | |
| Complete response | 22 |
| Partial response | 5 |
| Stable disease | 4 |
| Progressive disease | 1 |
| Characteristic . | Value . |
|---|---|
| No. | 32 |
| Median age, y | 55 |
| Range | 18-81 |
| Sex, male/female | 20/12 |
| Stage | |
| IE | 19 |
| IIE | 3 |
| IV | 10 |
| B-symptom (%) | 13 (41) |
| LDH elevation (%) | 12 (38) |
| Performance status > 1 (%) | 4 (13) |
| International Prognostic Index high-intermediate/high (%) | 10 (31) |
| Origin | |
| Nasal | 29 |
| Extranasal | 3 |
| Treatment | |
| Radiotherapy | 2 |
| Concurrent chemoradiotherapy | 16 |
| Radiotherapy followed by chemotherapy | 8 |
| Chemotherapy | 6 |
| Response | |
| Complete response | 22 |
| Partial response | 5 |
| Stable disease | 4 |
| Progressive disease | 1 |